Professor Pamela Russell

PhD (Autoimmunity), MSc (Autoimmunity), BSc (Biochemistry/Microbiology), DipEd

Head of Biomedical Imaging and Prostate Cancer Models, Australian Prostate Cancer Research Centre - Queensland

Research Themes

Cancer and Blood Diseases


Theranostic Development for Prostate Cancer

Currently involved in Theranostic Development for Prostate Cancer, a TRI based research project.

About me

Prof Russell joined the Australian Prostate Cancer Research Centre - Queensland (APCRC–Q) in 2009 where she holds the position of Professor, Head of Biomedical Imaging and Prostate Cancer Models. Prof Russell is a member of the Institute of Health and Biomedical Innovation, Queensland University of Technology working in translational studies in prostate cancer. Her current work focuses on the development of new animal models to study bony metastasis from prostate cancer. Prof Russell also investigates the development of theranostics, - nanotechnology for real time imaging for diagnosis and therapeutic delivery, including gene therapy of prostate cancer, and finding biomarkers from exosomes to predict treatment response in patients undergoing therapy.

Prof Russell trained in immunology at Walter & Eliza Hall Institute, where she obtained an MSc with Sir Macfarlane Burnet and a PhD with Sir Gustav Nossal, on studies of autoimmune diseases. She then trained at John Curtin School of Medical Research, Canberra, and at Kolling Institute of Medical Research. In 1984, Prof Russell changed her research focus to cancer and, with Dr Derek Raghavan, established the Urological Cancer Research Centre at Royal Prince Alfred Hospital/University of Sydney. Prof Russell then directed the Oncology Research Centre (ORC), Prince of Wales Hospital from 1992 to 2010, as conjoint Professor of Medicine, University of New South Wales (UNSW).

Prof Russell has built an international reputation for work on bladder and prostate cancer, with expertise for establishing cell lines and rare xenografts from primary human tumours. She collaborates widely, within Australia and overseas in USA and Europe.

She has supervised several postgraduate students, and since 2008 she has delivered presentations or chaired sessions at 14 international prostate cancer meetings.

Nationally, she helped to initiate the Australian Genitourinary Oncology Group and the Prostate Cancer Foundation of Australia (PCFA) (of which she is a life member). From 2007 to 2010 Prof Russell served as an inaugural Director/Secretary of the Australasian Urological and Prostate Cancer Clinical Trials Group (ANZUP). She is also an Australian editor for Urological Research and a member of Movember’s Global Scientific Committee.

Prof Russell has been on peer review committees for the National Health and Medical Research Committee (NHMRC), Cancer Council Australia, Cure Cancer Australia, and regularly reviews papers from international journals.


  • Singh P, Joshi S, Russell PJ, Verma N, Wang XC, Khatri A. Molecular chemotherapy and Chemotherapy: A new front against late stage hormone refractory prostate cancer. Clinical Cancer Research. 2011; 17(12): 1–13
  • Hung TT, Chan J, Russell PJ, Power CA. Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. PLoS ONE . 2011, 6(5): e19389, 1-8
  • Tang C, Russell PJ, Martiniello-Wilks R, Rasko J, Khatri A. Concise Review: Nanoparticles and cellular carriers - allies in imaging and therapy? Stem cells. 2010; 28(9):1686-702-702
  • Khatri A, Husaini Y,  Ow K, Chapman J, Russell PJ. Cytosine Deaminase-Uracil Phosphoribosyl Transferase and Interleukin-12 and -18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res.2009; 15(7):2323-2234.
  • Li Y, Song E, Rizvi SMA,  Power CA,  Beretov J, Raja C, Cozzi PJ, Morgenstern A, Apostolidis C, Allen BJ,  Russell PJ. Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bi-labeled multiple targeted a radioimmunoconjugates. Clin Cancer Res. 2009; 15:865-875

    More publications are available on PubMed

    Research fields

    prostate cancer, nanoparticles for imaging and delivery of chemotherapy, gene therapy for late stage prostate cancer, exosomes (small vesicles secreted by cancer cells), origin of cancer cells, identifying biomarkers from protein, miRNA, RNA, DNA or lipid


    ORCIDGoogle Scholar